de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2017;19(4):439–47.

Article  PubMed  Google Scholar 

Bull MJ. Down syndrome. N Engl J Med. 2020;382(24):2344–52.

Article  PubMed  Google Scholar 

Gardiner K. Gene-dosage effects in Down syndrome and trisomic mouse models. Genome Biol. 2004;5(10): 244.

Article  PubMed  PubMed Central  Google Scholar 

Moldrich RX, Dauphinot L, Laffaire J, Rossier J, Potier MC. Down syndrome gene dosage imbalance on cerebellum development. Prog Neurobiol. 2007;82(2):87–94.

Article  CAS  PubMed  Google Scholar 

Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 2023;22(1):55–65.

Article  CAS  PubMed  Google Scholar 

Chen XQ, Zuo X, Becker A, Head E, Mobley WC. Reduced synaptic proteins and SNARE complexes in down syndrome with Alzheimer’s disease and the Dp16 mouse down syndrome model: impact of APP gene dose. Alzheimers Dement. 2023;19(5):2095–116.

Article  CAS  PubMed  Google Scholar 

Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15(3):135–47.

Article  PubMed  PubMed Central  Google Scholar 

Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021;174(4):572–6.

Article  PubMed  Google Scholar 

Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. 2007;24(3):317–20.

Article  PubMed  Google Scholar 

Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia. 2006;49(6):1179–82.

Article  CAS  PubMed  Google Scholar 

Boucher AC, Caldwell KJ, Crispino JD, Flerlage JE. Clinical and biological aspects of myeloid leukemia in Down syndrome. Leukemia. 2021;35(12):3352–60.

Article  PubMed  PubMed Central  Google Scholar 

Chung H, Green PHR, Wang TC, Kong XF. Interferon-driven immune dysregulation in Down syndrome: a review of the evidence. J Inflamm Res. 2021;14:5187–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kong XF, Worley L, Rinchai D, Bondet V, Jithesh PV, Goulet M, Nonnotte E, Rebillat AS, Conte M, Mircher C, et al. Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. J Clin Immunol. 2020;40(6):807–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malle L, Bogunovic D. Down syndrome and type I interferon: not so simple. Curr Opin Immunol. 2021;72:196–205.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malle L, Martin-Fernandez M, Buta S, Richardson A, Bush D, Bogunovic D. Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. Immunity. 2022;55(11):2074–84.e2075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin M, Xu R, Wang L, Alam MM, Ma Z, Zhu S, Martini AC, Jadali A, Bernabucci M, Xie P, et al. Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer’s disease. Cell Stem Cell. 2022;29(7):1135–53.e1138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chi C, Knight WE, Riching AS, Zhang Z, Tatavosian R, Zhuang Y, Moldovan R, Rachubinski AL, Gao D, Xu H, et al. Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical wnt signaling. iScience. 2023;26(7): 107012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haller O, Kochs G, Weber F. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev. 2007;18(5–6):425–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778–809 (table of contents).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonaros F, Zenatelli R, Guerri G, Bertelli M, Locatelli C, Vione B, Catapano F, Gori A, Vitale L, Pelleri MC, et al. The transcriptome profile of human trisomy 21 blood cells. Hum Genom. 2021;15(1):25.

Article  CAS  Google Scholar 

Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol. 2008;26(7):817–23.

Article  CAS  PubMed  Google Scholar 

Izuta S, Ueki M, Ueno M, Nishina K, Shiozawa S, Maekawa N. T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice. Biotechnol Lett. 2012;34(12):2175–82.

Article  CAS  PubMed  Google Scholar 

Uchihashi S, Fukumoto H, Onoda M, Hayakawa H, Ikushiro S, Sakaki T. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms. Drug Metab Dispos. 2011;39(5):803–13.

Article  CAS  PubMed  Google Scholar 

Wang HN, Ji K, Zhang LN, Xie CC, Li WY, Zhao ZF, Chen JJ. Inhibition of c-Fos expression attenuates IgE-mediated mast cell activation and allergic inflammation by counteracting an inhibitory AP1/Egr1/IL-4 axis. J Transl Med. 2021;19(1):261.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye N, Ding Y, Wild C, Shen Q, Zhou J. Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem. 2014;57(16):6930–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng D, Chen Y, Dai R, Bian S, Xue W, Zhu Y, Li Z, Yang Y, Zhang Y, Zhang J, et al. Chromatin organizer SATB1 controls the cell identity of CD4(+) CD8(+) double-positive thymocytes by regulating the activity of super-enhancers. Nat Commun. 2022;13(1):5554.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Ye X, Dai R, Li Z, Zhang Y, Xue W, Zhu Y, Feng D, Qin L, Wang X, et al. Phase separation of Epstein-Barr virus EBNA2 protein reorganizes chromatin topology for epigenetic regulation. Commun Biol. 2021;4(1):967.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52.

Article  CAS  PubMed  Google Scholar 

Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, Jagodnik KM, Kropiwnicki E, Wang Z. Ma’ayan A: ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47(W1):W212–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, Chen CH, Brown M, Zhang X, Meyer CA, et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47(D1):D729–35.

Article  CAS  PubMed  Google Scholar 

Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, Cooper GM, Reddy TE, Crawford GE, Myers RM. Distinct properties of cell-type-specific and shared transcription factor binding sites. Mol Cell. 2013;52(1):25–36.

Article  CAS  PubMed  Google Scholar 

Meharena HS, Marco A, Dileep V, Lockshin ER, Akatsu GY, Mullahoo J, Watson LA, Ko T, Guerin LN, Abdurrob F, et al. Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors. Cell Stem Cell. 2022;29(1):116–30.e117.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi W, Yang F, Dai R, Sun Y, Chu Y, Liao S, Hao B. METTL3-mediated N6-methyladenosine modification is involved in the dysregulation of NRIP1 expression in Down syndrome. Front Cell Dev Biol. 2021;9: 621374.

Article  PubMed  PubMed Central